Showing results (351-360 of 421) with videos related to

Sort By:
Pageof 43
Frontiers in Stroke|January 16, 2026
Cathepsin L and acute ischemic stroke: A mini-reviewLinda Ma, Silin Wu, Aaron M Gusdon, et al.
Genetics and Molecular Research : GMR|December 5, 2015
Effects of choice of month of treatment and parity order on bovine superovulation traitsQ Deng, Y Gao, C H Li, et al.
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|July 7, 1999
Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLFK W Foster, S Ren, I D Louro, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|August 2, 2017
[Economic burden of stomach cancer in China during 1996-2015: a systematic review]F Yao, C L Shi, C C Liu, et al.
Human Molecular Genetics|January 12, 2001
Neurological abnormalities in a knock-in mouse model of Huntington's diseaseC H Lin, S Tallaksen-Greene, W M Chien, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|December 30, 2020
[Diagnostic performance of quantitative fecal immunochemical test in detection of advanced colorectal neoplasia]M Lu, H D Chen, C C Liu, et al.
Journal of Clinical Epidemiology|June 16, 2004
No racial differences in mortality found among Veterans Health Administration out-patientsAlfredo J Selim, Graeme Fincke, Dan R Berlowitz, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|June 4, 2005
Comprehensive health status assessment of centenarians: results from the 1999 large health survey of veteran enrolleesAlfredo J Selim, Graeme Fincke, Dan R Berlowitz, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|December 10, 2020
[Disease burden of colorectal cancer in China: any changes in recent years?]H Wang, M D Cao, C C Liu, et al.
ESMO Open|June 4, 2024
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancerA Grinshpun, S Ren, N Graham, et al.
Pageof 43